Natural Capsules Peer Comparison

NSE: NATCAPSUQ | BSE: 524654

₹214.16

₹33.88 (18.79%)

As on 27-Aug-2026IST

Market cap

₹223 Cr

Revenue (TTM)

₹191 Cr

P/E Ratio

P/B Ratio

Div. Yield

0 %

Edit

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	223	21,701	19,356	17,804	18,190
Revenue (₹ Cr)	191	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	-24.83	735.15	678.07	169.62	666.92
Net Margin (%)	-12.77	26.88	28.10	6.90	20.60
RoE (%)	-9.60	19.16	19.73	20.76	18.75
Price to Earnings	--	29.52	29.09	104.97	28.25
Price-To-Book	1.04	4.92	5.14	19.69	4.50

Income Statement (₹ Cr)

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	187.20	2,519.65	1,937.47	2,275.58	2,893.64
Total Income	190.63	2,707.60	2,033.90	2,304.07	2,912.00
Total Expenditure	189.78	1,615.47	1,290.54	2,013.55	1,876.44
EBITDA	-2.58	904.18	646.93	262.03	1,017.20
Depreciation	17.14	57.73	65.96	28.58	315.46
EBIT	-19.72	846.45	580.97	233.45	701.74
Interest	11.62	9.57	0.61	4.49	231.29
Other Income	3.42	187.95	96.43	28.49	18.36
Exceptional Items	--	-49.16	--	-5.25	--
Profit before Tax	-27.92	975.67	676.78	252.20	488.87
Provision for Tax	-3.26	253.24	135.69	64.68	114.20
Profit after Tax	-24.66	722.43	541.09	187.52	374.67

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	221.64	4,202.90	2,850.49	872.79	2,854.36
Minority Interest	13.09	--	35.90	--	417.40
Non-Current Liabilities	54.07	19.19	13.24	394.49	2,100.97
Current Liabilities	132.73	627.48	305.99	1,109.50	1,489.55
Total Liabilities	424.16	4,921.88	3,207.85	2,414.58	6,862.28

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	284.73	1,046.35	1,071.67	509.16	5,531.13
Current Assets	136.80	3,803.22	2,133.95	1,859.88	1,331.15
Total Assets	424.16	4,921.88	3,207.85	2,414.58	6,862.28
Total Debt*	114.34	2.50	0.55	0.00	2,421.66
Net Current Assets	4.07	3,175.74	1,827.96	750.38	-158.40
Contingent Liabilities	75.24	370.49	0.64	121.23	64.29

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	10.92	967.57	432.37	-15.14	1,065.01
Cash Flow from Investing Activities	-10.77	-561.67	-334.73	18.69	-79.97
Cash from Financing Activities	-0.62	-798.31	-38.32	-91.97	-881.32
Net Cash Inflow / Outflow	-0.47	-392.41	59.32	-88.42	103.72

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	-4.85	23.39	26.22	31.24	13.59
ROE (%)	-10.89	17.16	21.72	23.02	13.81
ROA (%)	-5.87	14.91	18.37	8.90	5.48
EBIT Margin (%)	0.45	43.34	38.37	12.77	35.79
Net Margin (%)	-12.94	26.68	26.60	8.14	12.87
Cash Profit Margin (%)	-4.02	29.72	31.33	9.47	23.22

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	10.64	10.45	14.37	32.59	44.02
EBIT Growth (%)	-95.41	19.68	20.21	-1.38	48.22
Net Profit Growth (%)	-4,094.72	-5.88	17.27	62.02	-5.65
EPS Growth (%)	-4,077.60	-5.88	17.25	62.02	-10.39
Book Value Growth (%)	-5.21	-0.34	23.77	13.51	10.19

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	0.00	29.89	28.38	103.45	54.83
Price / Book Value	0.68	5.14	5.52	22.39	6.78
Dividend Yield (%)	0.00	1.59	0.30	0.46	0.52
EV/EBITDA	306.59	16.93	19.78	65.23	20.75
Market Cap (₹ Cr)	149.97	21,592.90	15,219.80	19,398.64	19,292.77

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.52	0.00	0.00	0.00	0.85
Short term debt to equity ratio	0.20	0.00	0.00	--	0.14
Current Ratio	1.03	6.06	6.97	1.68	0.89
Quick Ratio	0.83	5.31	5.88	0.75	0.67
Interest Coverage	-1.40	102.95	1,110.48	57.17	3.11

	Natural Capsules	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	38.12	7.22	32.65	9.39	15.85
Asset Turnover	0.45	0.54	0.66	1.08	0.43
Receivable days	130.24	26.06	110.70	31.88	54.07
Inventory Days	50.48	65.95	65.86	126.03	32.16
Payable days	167.31	81.01	105.88	163.79	140.91
Cash Conversion Cycle	13.41	11.00	70.68	-5.88	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.